Skip to content

Avocado Consumption and Cellular Aging in Breast Cancer Survivors

Effect of Daily Avocado Consumption on Cellular Aging in Female Breast Cancer Survivors: The ACCA Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07097155
Acronym
ACCA
Enrollment
120
Registered
2025-07-31
Start date
2026-01-12
Completion date
2027-08-01
Last updated
2026-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer Females, Telomere Length

Keywords

Avocado consumption, Telomere length, Breast Cancer

Brief summary

Women with breast cancer are at increased risk of comorbidities and premature mortality, potentially due to accelerated biological aging. Telomere attrition has been proposed as a biomarker of this process, which could be mitigated through interventions targeting behavioral factors such as diet. In recent years, avocado has drawn attention in nutritional research due to its unique nutritional profile. Main objective: To evaluate the effect of consuming one avocado per day on biological aging-measured by telomere length-in breast cancer survivors, compared to a habitual diet (less than two avocados per week). Secondary objectives include changes in telomerase activity and biomarkers of inflammation and oxidative stress. Additional objectives include classical cardiovascular disease markers (glucose metabolism, lipid profile, blood pressure); anthropometric measurements; symptoms of depression and anxiety; quality of life and fatigue; and diet quality. Methodology: A randomized controlled parallel-group trial involving 120 breast cancer survivors. Participants will be randomly assigned to either the intervention group (one avocado per day) or the control group (habitual diet with fewer than two avocados per week) and followed for 4 months. At baseline and the end of the intervention, a general questionnaire will be administered; blood and urine samples will be collected; anthropometric and blood pressure measurements will be taken; and diet, physical activity, symptoms of depression and anxiety, quality of life, and fatigue will be assessed. Mean changes from baseline to the end of the intervention in the primary outcome (telomere length) and secondary outcomes (inflammation, oxidative stress, classical cardiovascular disease markers, anthropometric measures, symptoms of depression and anxiety, quality of life, and diet) will be compared between the intervention and control groups using linear regression models.

Interventions

OTHERDaily Avocado Consumption

Participants follow their usual diet and consume one avocado per day for 4 months

Sponsors

Institut Investigacio Sanitaria Pere Virgili
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
40 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Women diagnosed with primary breast cancer in stages I, II or III; * 40-65 years old at screening; * Cancer treatment (radiotherapy and chemotherapy) completed ≥ 6 months but not more than 10 years at the time of recruitment; * Currently consuming less than 2 avocados per week; * Signed the informed consent letter.

Exclusion criteria

* Metastasis; * Ductal carcinoma or lobular carcinoma in situ; * Breast cancer recurrence; * Cancer diagnosis other than breast cancer or non-melanoma skin cancer; * Body mass index ≥40kg/m2; * Currently pregnant or breastfeeding, or planning pregnancy in the following 6 months; * Allergy to latex; * Unwilling to consume avocado; * Immunodeficiency or HIV-positive status; * Alcohol abuse (\>50g/day); * Unstable use of plant sterols, mineral supplements, use of fibre supplements, fish oil, or antioxidants in the 4 weeks prior to enrolment, or plans to change this during the study; * Currently participating in any other randomized controlled trial; * Difficulty or impossibility of an adequate follow-up; * Inability or unwillingness to give written informed consent or to communicate with study personnel, or illiteracy; * Patients with an acute infection or inflammation (e.g., pneumonia) will be allowed to participate in the study 3 months after recovery.

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in leukocyte telomere lengthParticipants will be followed for 4 months. Measurements will be done before and after 4 months.Telomere length (TL) analysis will be performed employing the traditional real-time PCR(1) method (Cawthon 2009) by the QuantiTect Syber Green PCR kit (Qiagen). This approach employs the 36B4R single-copy gene as a reference for each sample. The measurements will be performed on a monochrome multiplex real-time quantitative PCR in a BioradCFX96 thermocycler on samples collected before and after the intervention. The data obtained by PCR will be expressed as the ratio of telomere/reference gene (T / S) as the ratio between the number of copies of the telomeric repeat (T) and a single copy gene (36B4F) (S)

Secondary

MeasureTime frameDescription
Change from baseline in telomerase activityParticipants will be followed for 4 months. Measurements will be done before and after 4 months.Telomerase activity will be assessed in white blood cells (PBMCs) using the TeloTAGGG Telomerase PCR ELISAPLUS method, a photometric enzyme immunoassay for quantitative determination of telomerase activity, utilizing the Telomeric Repeat Amplification Protocol (TRAP) (Sigma Aldrich).
Change from baseline in inflammatory markersParticipants will be followed for 4 months. Measurements will be done before and after 4 months.Blood samples will be collected in the morning after 8-12h fast. Inflammatory markers (C-reactive protein, IL-1β, IL-6, TNFα, IL-8, IL-10) will be measured by commercial ELISA.
Change from baseline in oxidative markersParticipants will be followed for 4 months. Measurements will be done before and after 4 months.Blood samples will be collected in the morning after an 8-12h fast. Oxidized LDL will be measured in plasma. Spot urine will be collected, and 8-iso-prostaglandin F2α (8-isoprostanes) will be measured.

Countries

Spain

Contacts

CONTACTNerea Becerra Tomás, PhD
nerea.becerra@urv.cat+34977759334
CONTACTVictoria Arija, Professor
victoria.arija@urv.cat+34977759334

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 13, 2026